The computer simulated model took into account the launch of direct-acting antiviral medications, increasing availability of oral drug therapies, development of new drugs and CDC-recommended guidelines of screening for people born between 1945 and 1965.
The model also predicted these factors in combination with the wider availability of recently approved treatments would reduce the number of new cirrhosis cases by 124,200, the number of hepatocelluar carcinoma cases by 78,000, the number of liver transplants by 9,900 and the number of liver-related deaths by 126,500, according to the report.
More articles on gastroenterology:
3 devices designed to improve CRC detection rates & care
GRHealth opens Digestive Health Center in new location
How has healthcare reform affected gastroenterology?
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.